Evaluation Of Non-Hematological And Hepatic Toxicities Developed During Chemotherapy Treatment And Role Of Liver Enzymes In Disease Prognosis

Authors: Uzma Raza, Aziza Khanam, S. Najeeb Naimatullah, Amir Maqbool, Saleemul Haque

1. HAMDARD COLLEGE OF MEDICINE AND DENTISTRY, HAMDARD UNIVERSITY, KARACHI, PAKISTAN.
2. UNIVERSITY OF KARACHI, KARACHI, PAKISTAN.
3. LIAQUAT NATIONAL HOSPITAL, KARACHI AND AGA KHAN UNIVERSITY, HOSPITAL, KARACHI, PAKISTAN.
4. KARACHI INSTITUTE OF RADIOTHERAPY AND NUCLEAR MEDICINE (KIRAN)
5. AV CENNA MEDICAL COLLEGE, LAHORE.

Volume 16 | Issue 1

Published: November 8, 2026

Abstract

To evaluate the non-hematological toxicities and liver enzymes alterations in breast cancer patients after chemotherapy treatment. To assess the role of liver enzymes in disease prognosis. Patients And Method: 224 female breast cancer patients initially diagnosed with primary breast cancer in one breast, without metastasis to distant organs were selected from the oncology unit of the teaching hospital. Patients were divided in two groups on the basis of dissected lymph node(s) with and without metastasis. 224 female subjects without cancer history were selected as control. The blood samples were evaluated for liver function test. Breast cancer treatment was prescribed to breast cancer patients by the oncologist and included combinations of surgery, chemotherapy, radiotherapy and hormonal therapy. 201 patients were treated by chemotherapy included treatment and were evaluated for the non-hematological toxicities developed by the treatment. 23 patients included in the study were treated without chemotherapy and the treatment included surgery, radiotherapy and hormonal therapy. Blood samples of all the patients were evaluated for liver function, to assess the liver toxicity, 14 weeks after the last chemotherapy dose. During this period patients were treated for six weeks with radiotherapy and eight weeks with hormonal therapy, which later continued for five years. Results: Alopecia was experienced by all patients. High percentage of patients suffered weight loss, fatigue and nail changes. Toxicities experienced were grade I and II and were reversible. No incidence of death was reported on chemotherapy treatment. Evaluation of liver enzymes at disease presentation reported significantly high alanine transaminase level in patients with axillary lymph node metastasis as compared to control subjects and in patients treated without Hormonal therapy (p<0.05). In breast cancer patients alkaline phosphatase was significantly high after chemotherapy treatment as compared to that before treatment (p<0.05). No significant change in bilirubin levels was observed. Nolvodex was excluded as toxicity inducing factor since, exposure of patients with hormonal therapy was less than the period required to produce toxicity. Conclusion: We conclude that toxicities experienced by the breast cancer patients after chemotherapy treatment were mild and reversible. Significantly raised alanine transaminase in patients with lymph node metastasis at disease presentation before starting the treatment is suggestive of its role in disease prognosis. Alanine transaminase level was significantly high in patients treated without hormonal therapy included treatment, thus indicating the protective effect of hormonal therapy on liver enzyme. Significantly high alkaline phosphatase level after chemotherapy treatment shows the relation between chemotherapy and hepatic toxicity development. Hormonal therapy does not participate in toxicity development.

Keywords: Breast Cancer, Hepatic Toxicity, Liver Enzymes

DOI: (All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.)

Download Full Text PDF